Morgan Stanley Maintains Equal-Weight on Repare Therapeutics, Lowers Price Target to $14
Morgan Stanley analyst Jeffrey Hung maintains Repare Therapeutics (NASDAQ:RPTX) with a Equal-Weight and lowers the price target from $15 to $14.
Credit Suisse, Autodesk And Other Big Losers From Wednesday
U.S. stocks closed higher on Wednesday, with the Nasdaq Composite gaining more than 100 points. Here is the list of some big stocks recording losses in the previous session.
The Daily Biotech Pulse: Roche’s Alzheimer’s Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
Here's a roundup of top developments in the biotech space over the last 24 hours:
HC Wainwright & Co. Maintains Buy on Repare Therapeutics, Lowers Price Target to $38
HC Wainwright & Co. analyst Robert Burns maintains Repare Therapeutics (NASDAQ:RPTX) with a Buy and lowers the price target from $54 to $38.
Mid-Afternoon Market Update: Dow Surges Over 200 Points; Immunic Shares Slide
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Thursday.
Mid-Day Market Update: U.S. Stocks Turn Positive; Nasdaq Jumps 150 Points
U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining 150 points on Thursday.
Piper Sandler Maintains Overweight on Repare Therapeutics, Raises Price Target to $30
Piper Sandler analyst Joseph Catanzaro maintains Repare Therapeutics (NASDAQ:RPTX) with a Overweight and raises the price target from $25 to $30.
